

Mannix Auger-Messier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1725154/publications.pdf>

Version: 2024-02-01

25
papers

600
citations

687363

13
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

713
citing authors

#	ARTICLE	IF	CITATIONS
1	Size-Reduced Macrocyclic Analogues of [Pyr ¹]-apelin-13 Showing Negative G_{12} Bias Still Produce Prolonged Cardiac Effects. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 531-551.	6.4	7
2	Monitoring TRPC7 Conformational Changes by BRET Following GPCR Activation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2502.	4.1	1
3	Structure-Activity Relationship and Bioactivity of Short Analogues of ELABELA as Agonists of the Apelin Receptor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 602-615.	6.4	9
4	Constraining the Side Chain of C-Terminal Amino Acids in Apelin-13 Greatly Increases Affinity, Modulates Signaling, and Improves the Pharmacokinetic Profile. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5345-5364.	6.4	10
5	Cardiomyocyte-specific Srsf3 deletion reveals a mitochondrial regulatory role. <i>FASEB Journal</i> , 2021, 35, e21544.	0.5	1
6	G_{12} -biased apelin analog protects against isoproterenol-induced myocardial dysfunction in rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H1646-H1656.	3.2	6
7	Apelin-13 in septic shock: effective in supporting hemodynamics in sheep but compromised by enzymatic breakdown in patients. <i>Scientific Reports</i> , 2021, 11, 22770.	3.3	5
8	The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders. <i>Annals of the New York Academy of Sciences</i> , 2019, 1455, 12-33.	3.8	46
9	p38 β MAPK proximity assay reveals a regulatory mechanism of alternative splicing in cardiomyocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 118557.	4.1	14
10	MURC/CAVIN-4 facilitates store-operated calcium entry in neonatal cardiomyocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 1249-1259.	4.1	10
11	Apelins, ELABELA, and their derivatives: Peptidic regulators of the cardiovascular system and beyond. <i>Peptide Science</i> , 2019, 111, e24064.	1.8	7
12	Involvement of MURC/Cavin-4 in store-operated Ca ²⁺ entry in neonatal cardiomyocytes. <i>FASEB Journal</i> , 2019, 33, .	0.5	0
13	A Systematic Exploration of Macrocyclization in Apelin-13: Impact on Binding, Signaling, Stability, and Cardiovascular Effects. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2266-2277.	6.4	30
14	The apelinergic system as an alternative to catecholamines in low-output septic shock. <i>Critical Care</i> , 2018, 22, 10.	5.8	17
15	The hypotensive effect of activated apelin receptor is correlated with β -arrestin recruitment. <i>Pharmacological Research</i> , 2018, 131, 7-16.	7.1	23
16	ADAP1 limits neonatal cardiomyocyte hypertrophy by reducing integrin cell surface expression. <i>Scientific Reports</i> , 2018, 8, 13605.	3.3	11
17	Apelin Compared With Dobutamine Exerts Cardioprotection and Extends Survival in a Rat Model of Endotoxin-Induced Myocardial Dysfunction*. <i>Critical Care Medicine</i> , 2017, 45, e391-e398.	0.9	30
18	Structure-activity relationship of novel macrocyclic biased apelin receptor agonists. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 449-458.	2.8	27

#	ARTICLE	IF	CITATIONS
19	ELABELA Improves Cardio-Renal Outcome in Fatal Experimental Septic Shock. <i>Critical Care Medicine</i> , 2017, 45, e1139-e1148.	0.9	49
20	Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2962-2972.	6.4	100
21	C-Terminal Modifications of Apelin-13 Significantly Change Ligand Binding, Receptor Signaling, and Hypotensive Action. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2431-2440.	6.4	48
22	Unrestrained p38 MAPK Activation in <i>Dusp1/4</i> Double-Null Mice Induces Cardiomyopathy. <i>Circulation Research</i> , 2013, 112, 48-56.	4.5	78
23	The constitutively active N111G-AT1 receptor for angiotensin II modifies the morphology and cytoskeletal organization of HEK-293 cells. <i>Experimental Cell Research</i> , 2005, 308, 188-195.	2.6	15
24	Down-Regulation of Inositol 1,4,5-Trisphosphate Receptor in Cells Stably Expressing the Constitutively Active Angiotensin II N111G-AT1 Receptor. <i>Molecular Endocrinology</i> , 2004, 18, 2967-2980.	3.7	25
25	The Constitutively Active N111G-AT1 Receptor for Angiotensin II Maintains a High Affinity Conformation Despite Being Uncoupled from Its Cognate G Protein Gq/11 β . <i>Endocrinology</i> , 2003, 144, 5277-5284.	2.8	31